Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Trial Details

NCT ID
NCT06150898
Phase
PHASE2
Sponsor
Jules Bordet Institute
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Prospective data and sample collection
  • Ketorolac 10 Mg Oral Tablet
  • Pregabalin 75mg
  • Omeprazole 20mg Capsule
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Subjects must meet all of the following criteria in order to be eligible for this study:
  • Age ≥ 18 years and ≤ 70 years old
  • Weight ≥ 35 kg
  • Histological diagnosis of invasive breast adenocarcinoma that is estrogen receptor positive as per the updated American Society of Clinical Oncolog…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →